Theravance MRSA drug a victim of Ben Venue shutdown

Vibativ, an injectable skin-infection treatment from Theravance ($THRX) that's marketed by Astellas, has fallen victim to the QA-related production shutdown at contractor Ben Venue's plant in Bedford, OH. Theravance spokesperson Cheryllyn De Ocampo confirmed by email the speculation in Friday's San Francisco Business Times.

According to Reuters, an Astellas letter informed wholesalers, distributors and the healthcare community of a hold on distribution and cited "critical product shortages [and] regional supply outages." Astellas has recommended that no new patients begin treatment with the drug, which fights gram-positive bacteria, including MRSA.

The once-daily injectable won European approval last September. It was approved in the U.S. in 2009.

Ben Venue, a unit of Boehringer Ingelheim, voluntarily suspended drug manufacturing and distribution at the Bedford plant after a joint visit by inspectors from the FDA, France and the U.K.

- see the San Francisco Business Times column
- here's the Reuters story

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)